Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition Disorders | 24 | 2016 | 370 | 2.450 |
Why?
|
| Brain Concussion | 16 | 2022 | 65 | 1.890 |
Why?
|
| Schizophrenia | 10 | 2016 | 32 | 1.370 |
Why?
|
| Neuropsychological Tests | 30 | 2020 | 363 | 1.320 |
Why?
|
| Brain Injuries | 13 | 2015 | 91 | 0.920 |
Why?
|
| Athletic Injuries | 9 | 2020 | 95 | 0.850 |
Why?
|
| Schizophrenic Psychology | 5 | 2012 | 9 | 0.680 |
Why?
|
| Magnetic Resonance Imaging | 20 | 2016 | 1307 | 0.630 |
Why?
|
| Image Processing, Computer-Assisted | 11 | 2018 | 225 | 0.620 |
Why?
|
| Hockey | 8 | 2015 | 10 | 0.620 |
Why?
|
| Alzheimer Disease | 10 | 2012 | 302 | 0.610 |
Why?
|
| Brain | 11 | 2018 | 946 | 0.590 |
Why?
|
| Hippocampus | 4 | 2015 | 171 | 0.540 |
Why?
|
| Memory Disorders | 8 | 2016 | 54 | 0.520 |
Why?
|
| Memory | 9 | 2018 | 191 | 0.470 |
Why?
|
| Adult | 40 | 2022 | 9569 | 0.450 |
Why?
|
| Humans | 72 | 2022 | 32814 | 0.450 |
Why?
|
| Diffusion Tensor Imaging | 6 | 2020 | 31 | 0.450 |
Why?
|
| Awareness | 3 | 2009 | 29 | 0.440 |
Why?
|
| Amnesia | 3 | 2010 | 8 | 0.440 |
Why?
|
| Male | 53 | 2020 | 19650 | 0.440 |
Why?
|
| Female | 53 | 2020 | 20271 | 0.430 |
Why?
|
| Cognition | 6 | 2017 | 551 | 0.410 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2018 | 54 | 0.400 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2018 | 49 | 0.390 |
Why?
|
| Frontal Lobe | 5 | 2010 | 37 | 0.390 |
Why?
|
| Young Adult | 18 | 2022 | 2734 | 0.350 |
Why?
|
| Memory, Short-Term | 5 | 2017 | 60 | 0.330 |
Why?
|
| Automation | 1 | 2010 | 30 | 0.320 |
Why?
|
| Athletes | 6 | 2020 | 73 | 0.310 |
Why?
|
| Adolescent | 16 | 2022 | 3640 | 0.310 |
Why?
|
| Head Protective Devices | 6 | 2015 | 49 | 0.300 |
Why?
|
| Verbal Behavior | 2 | 2008 | 9 | 0.300 |
Why?
|
| Psychiatric Status Rating Scales | 9 | 2016 | 95 | 0.290 |
Why?
|
| Septum Pellucidum | 1 | 2007 | 2 | 0.260 |
Why?
|
| Mental Disorders | 3 | 2013 | 125 | 0.250 |
Why?
|
| Head | 3 | 2022 | 56 | 0.250 |
Why?
|
| Reaction Time | 6 | 2016 | 119 | 0.240 |
Why?
|
| Methylphenidate | 2 | 2016 | 36 | 0.240 |
Why?
|
| Geriatric Assessment | 1 | 2008 | 388 | 0.240 |
Why?
|
| Psychomotor Performance | 4 | 2016 | 99 | 0.230 |
Why?
|
| Middle Aged | 20 | 2018 | 12133 | 0.220 |
Why?
|
| Borderline Personality Disorder | 1 | 2004 | 3 | 0.210 |
Why?
|
| Parietal Lobe | 2 | 2006 | 13 | 0.210 |
Why?
|
| Amygdala | 2 | 2015 | 59 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2016 | 1066 | 0.210 |
Why?
|
| Hypothyroidism | 1 | 2003 | 12 | 0.200 |
Why?
|
| Psychotic Disorders | 3 | 2011 | 11 | 0.200 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2015 | 29 | 0.200 |
Why?
|
| Executive Function | 3 | 2016 | 56 | 0.200 |
Why?
|
| Depressive Disorder | 1 | 2003 | 77 | 0.200 |
Why?
|
| Brain Mapping | 4 | 2011 | 179 | 0.180 |
Why?
|
| Problem Solving | 4 | 2011 | 26 | 0.180 |
Why?
|
| Football | 4 | 2020 | 82 | 0.170 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 5 | 2011 | 26 | 0.170 |
Why?
|
| Dementia | 1 | 2003 | 245 | 0.170 |
Why?
|
| Models, Biological | 2 | 2014 | 392 | 0.160 |
Why?
|
| Psychometrics | 3 | 2016 | 137 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2018 | 112 | 0.160 |
Why?
|
| Accidents, Traffic | 1 | 2022 | 197 | 0.160 |
Why?
|
| Models, Neurological | 3 | 2018 | 119 | 0.160 |
Why?
|
| Emotions | 2 | 2017 | 59 | 0.160 |
Why?
|
| Aged | 14 | 2012 | 10544 | 0.160 |
Why?
|
| Acceleration | 5 | 2022 | 69 | 0.160 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 767 | 0.160 |
Why?
|
| Corpus Callosum | 2 | 2011 | 17 | 0.150 |
Why?
|
| Post-Concussion Syndrome | 1 | 2018 | 2 | 0.150 |
Why?
|
| Attention | 5 | 2016 | 82 | 0.140 |
Why?
|
| Veterans | 2 | 2016 | 69 | 0.140 |
Why?
|
| Aggression | 2 | 2015 | 30 | 0.140 |
Why?
|
| Students | 3 | 2016 | 179 | 0.140 |
Why?
|
| Health Surveys | 1 | 2018 | 200 | 0.140 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2017 | 6 | 0.130 |
Why?
|
| Thalamus | 2 | 2015 | 33 | 0.130 |
Why?
|
| Disease Progression | 3 | 2010 | 594 | 0.130 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 41 | 0.130 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 881 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 2285 | 0.130 |
Why?
|
| Malingering | 1 | 2016 | 5 | 0.130 |
Why?
|
| Epilepsies, Partial | 1 | 2016 | 9 | 0.130 |
Why?
|
| alpha-Synuclein | 1 | 2016 | 10 | 0.130 |
Why?
|
| Afghan Campaign 2001- | 1 | 2016 | 14 | 0.120 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2008 | 78 | 0.120 |
Why?
|
| Health Status | 1 | 2018 | 402 | 0.120 |
Why?
|
| Universities | 2 | 2015 | 153 | 0.120 |
Why?
|
| Case-Control Studies | 6 | 2008 | 877 | 0.120 |
Why?
|
| Social Behavior | 1 | 2016 | 64 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 78 | 0.120 |
Why?
|
| Galantamine | 1 | 2015 | 1 | 0.120 |
Why?
|
| Neostriatum | 1 | 2015 | 22 | 0.120 |
Why?
|
| Regional Blood Flow | 1 | 2015 | 85 | 0.120 |
Why?
|
| Brain Injury, Chronic | 1 | 2015 | 1 | 0.110 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2007 | 8 | 0.110 |
Why?
|
| Diffuse Axonal Injury | 1 | 2015 | 3 | 0.110 |
Why?
|
| Health Priorities | 1 | 2015 | 16 | 0.110 |
Why?
|
| Policy Making | 1 | 2015 | 19 | 0.110 |
Why?
|
| Violence | 1 | 2015 | 18 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2016 | 203 | 0.110 |
Why?
|
| Functional Laterality | 3 | 2010 | 56 | 0.110 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 95 | 0.110 |
Why?
|
| Safety | 1 | 2015 | 77 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2020 | 1844 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2016 | 226 | 0.110 |
Why?
|
| Statistics as Topic | 3 | 2010 | 104 | 0.110 |
Why?
|
| Linkage Disequilibrium | 3 | 2012 | 185 | 0.110 |
Why?
|
| Suicide | 1 | 2014 | 20 | 0.100 |
Why?
|
| Linear Models | 2 | 2016 | 445 | 0.100 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2013 | 2 | 0.100 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2013 | 7 | 0.100 |
Why?
|
| Dopamine Agonists | 2 | 2011 | 28 | 0.100 |
Why?
|
| Contrast Sensitivity | 1 | 2012 | 6 | 0.100 |
Why?
|
| Vision Disorders | 1 | 2012 | 26 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2016 | 525 | 0.090 |
Why?
|
| Time Factors | 3 | 2015 | 2183 | 0.090 |
Why?
|
| Software | 2 | 2010 | 124 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2012 | 37 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 126 | 0.090 |
Why?
|
| Guanfacine | 1 | 2011 | 5 | 0.090 |
Why?
|
| Bromocriptine | 1 | 2011 | 1 | 0.090 |
Why?
|
| Emotional Intelligence | 1 | 2010 | 2 | 0.080 |
Why?
|
| Aging | 2 | 2007 | 938 | 0.080 |
Why?
|
| Obsessive Behavior | 1 | 2010 | 3 | 0.080 |
Why?
|
| Compulsive Behavior | 1 | 2010 | 4 | 0.080 |
Why?
|
| Brain Stem | 1 | 2010 | 20 | 0.080 |
Why?
|
| Genotype | 4 | 2016 | 731 | 0.080 |
Why?
|
| Illness Behavior | 1 | 2009 | 2 | 0.080 |
Why?
|
| Brain Diseases | 1 | 2010 | 38 | 0.080 |
Why?
|
| Organ Size | 1 | 2010 | 219 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 134 | 0.080 |
Why?
|
| Risk Factors | 5 | 2014 | 3976 | 0.070 |
Why?
|
| Comorbidity | 3 | 2018 | 573 | 0.070 |
Why?
|
| Language Tests | 1 | 2008 | 5 | 0.070 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2008 | 49 | 0.070 |
Why?
|
| Antipsychotic Agents | 2 | 2007 | 28 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2013 | 828 | 0.070 |
Why?
|
| Exploratory Behavior | 1 | 2007 | 30 | 0.070 |
Why?
|
| Quality of Life | 3 | 2018 | 962 | 0.070 |
Why?
|
| Evoked Potentials | 1 | 2007 | 17 | 0.070 |
Why?
|
| Anisotropy | 2 | 2020 | 12 | 0.060 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2006 | 14 | 0.060 |
Why?
|
| Fornix, Brain | 1 | 2006 | 7 | 0.060 |
Why?
|
| Bipolar Disorder | 1 | 2006 | 15 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 526 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 87 | 0.060 |
Why?
|
| Pseudobulbar Palsy | 1 | 2005 | 5 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2005 | 21 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2004 | 18 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2016 | 3441 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2004 | 37 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2004 | 8 | 0.050 |
Why?
|
| Indans | 1 | 2004 | 34 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2003 | 4 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2003 | 21 | 0.050 |
Why?
|
| Thyroxine | 1 | 2003 | 16 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2003 | 31 | 0.050 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 35 | 0.050 |
Why?
|
| Affect | 1 | 2004 | 70 | 0.050 |
Why?
|
| Piperidines | 1 | 2004 | 120 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2011 | 459 | 0.050 |
Why?
|
| Huntington Disease | 1 | 2002 | 15 | 0.050 |
Why?
|
| Reference Values | 3 | 2007 | 238 | 0.050 |
Why?
|
| Alleles | 2 | 2016 | 253 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 307 | 0.040 |
Why?
|
| Child | 3 | 2015 | 2478 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2002 | 89 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1572 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 457 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 779 | 0.040 |
Why?
|
| Hospitalization | 1 | 2004 | 488 | 0.040 |
Why?
|
| Oxygen | 2 | 2011 | 144 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 676 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 576 | 0.040 |
Why?
|
| Observer Variation | 2 | 2012 | 96 | 0.040 |
Why?
|
| Trauma Severity Indices | 2 | 2011 | 49 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 949 | 0.040 |
Why?
|
| Personality Inventory | 2 | 2009 | 18 | 0.040 |
Why?
|
| Depression | 2 | 2016 | 448 | 0.030 |
Why?
|
| Syndrome | 2 | 2010 | 74 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2013 | 2329 | 0.030 |
Why?
|
| Task Performance and Analysis | 2 | 2007 | 54 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 223 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 292 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2016 | 3705 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2016 | 72 | 0.030 |
Why?
|
| Brief Psychiatric Rating Scale | 2 | 2007 | 3 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 208 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2015 | 17 | 0.030 |
Why?
|
| Minnesota | 1 | 2015 | 21 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 563 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 42 | 0.030 |
Why?
|
| United States | 2 | 2014 | 4109 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 240 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 175 | 0.030 |
Why?
|
| Skiing | 1 | 2013 | 2 | 0.030 |
Why?
|
| Track and Field | 1 | 2013 | 3 | 0.030 |
Why?
|
| Mental Health Services | 1 | 2014 | 31 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 77 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 565 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 215 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2014 | 65 | 0.030 |
Why?
|
| Paranoid Disorders | 1 | 2013 | 1 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2013 | 65 | 0.020 |
Why?
|
| Unconsciousness | 1 | 2012 | 3 | 0.020 |
Why?
|
| Sleep Stages | 1 | 2012 | 6 | 0.020 |
Why?
|
| Dizziness | 1 | 2012 | 12 | 0.020 |
Why?
|
| Neck Pain | 1 | 2012 | 6 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 511 | 0.020 |
Why?
|
| Headache | 1 | 2012 | 75 | 0.020 |
Why?
|
| New Hampshire | 1 | 2011 | 5 | 0.020 |
Why?
|
| Sports Equipment | 1 | 2011 | 7 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 259 | 0.020 |
Why?
|
| Telemetry | 1 | 2011 | 29 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 85 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1197 | 0.020 |
Why?
|
| Rotation | 1 | 2011 | 52 | 0.020 |
Why?
|
| Atrophy | 1 | 2011 | 46 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2011 | 83 | 0.020 |
Why?
|
| Prolactin | 1 | 2011 | 9 | 0.020 |
Why?
|
| Schools | 1 | 2011 | 67 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 98 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 126 | 0.020 |
Why?
|
| Cranial Nerve Diseases | 1 | 2010 | 5 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1002 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2009 | 10 | 0.020 |
Why?
|
| Self Concept | 1 | 2009 | 44 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 638 | 0.020 |
Why?
|
| DNA Replication | 1 | 2008 | 34 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 4034 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 220 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 220 | 0.020 |
Why?
|
| Behavioral Symptoms | 1 | 2007 | 4 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2007 | 27 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2007 | 10 | 0.020 |
Why?
|
| Cephalometry | 1 | 2007 | 19 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 783 | 0.020 |
Why?
|
| Receptors, Catecholamine | 1 | 2006 | 1 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2007 | 95 | 0.020 |
Why?
|
| Apolipoprotein E3 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Catecholamines | 1 | 2006 | 18 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 888 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2006 | 57 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 110 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2006 | 72 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2005 | 28 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 126 | 0.010 |
Why?
|
| Vocabulary | 1 | 2004 | 1 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 2004 | 1 | 0.010 |
Why?
|
| Semantics | 1 | 2004 | 12 | 0.010 |
Why?
|
| Intelligence | 1 | 2004 | 5 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2004 | 41 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 183 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 288 | 0.010 |
Why?
|
| Social Support | 1 | 2004 | 183 | 0.010 |
Why?
|
| Mass Screening | 1 | 2005 | 268 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 195 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 835 | 0.010 |
Why?
|
| Neoplasms | 1 | 2004 | 762 | 0.010 |
Why?
|